Potential Rett syndrome drug shows promising results in phase 3 trial

Vanderbilt Kennedy Center

The Promise of Discovery Season 2, Episode 7: This episode features a discussion of the need for meaningful therapies in Rett syndrome (RTT), and highlights the Lavender™ study, a phase 3, 12-week, double-blind, randomized, placebo-controlled study of the drug trofinetide in 187 young females, ages 5 to 20, with Rett syndrome. Investigators discuss public, top-level results of the potential first-of-its-kind drug to treat the symptoms of RTT, and share the hope that this trial paves the way for other successful trials in RTT and related disorders. VKC Researchers: Jeffrey L. Neul, M.D., Ph.D., Annette Schaffer Eskind Chair and Director, Vanderbilt Kennedy Center; Professor of Pediatrics, Division of Neurology, Pharmacology, and Special Education Cary Fu, M.D., Assistant Professor of Pediatrics, Pediatric Neurology

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada